Alphatec Spine Board Member Joins Paragon 28 to Enhance Orthopedic Leadership and Innovation

Paragon 28 Welcomes Orthopedic Leader Dave Demski to Board of Directors

Paragon 28, Inc., a leading provider of foot and ankle surgical solutions, announces the appointment of Dave Demski as an independent director, expanding its Board of Directors to nine members. Demski brings over two decades of extensive experience in the orthopedic sector, having previously served as President and CEO of Globus Medical. His tenure at Globus Medical, from August 2017 to April 2022, was marked by significant growth, innovation, and an unwavering commitment to advancing orthopedic practices. This new addition to the board reflects Paragon 28’s ongoing strategy to enhance leadership capabilities and drive innovation within the orthopedic market.

Demski’s impressive credentials include a diverse background in key operational roles, including Chief Financial Officer and Chief Operating Officer at Globus Medical. His depth of experience is complemented by his longstanding involvement in public company boards, having served on the board of Globus Medical since its inception and currently on the board of Alphatec Spine. His educational background, which includes a B.S. in Business Administration from the University of Michigan and an M.B.A. from Stanford Graduate School of Business, further strengthens his qualifications as a leader in the orthopedic field. Paragon 28’s Chairman and CEO, Albert DaCosta, expresses enthusiasm about Demski's appointment, highlighting the importance of his industry knowledge and operational expertise in fulfilling the company’s mission of improving patient outcomes in foot and ankle surgeries.

Demski expresses eagerness to contribute to Paragon 28’s objectives, emphasizing his commitment to innovation in the foot and ankle market. Paragon 28 is dedicated to developing advanced orthopedic solutions that address various conditions, from fracture fixation to flatfoot correction, while continuously seeking to enhance surgical outcomes and procedural efficiencies. The company’s focus on innovation positions it well to meet the evolving needs of the orthopedic market and improve patient lives.

In addition to this strategic appointment, Paragon 28 remains steadfast in its mission to lead in the foot and ankle surgery sector. The company continues to invest in research and development, ensuring it stays at the forefront of orthopedic advancements. With Demski on board, Paragon 28 aims to leverage his expertise to expand its innovative product offerings and improve patient care.

Overall, Demski’s addition to Paragon 28’s board underscores the company’s commitment to strengthening its leadership and advancing its mission within the orthopedic industry. As the company navigates the complexities of the healthcare landscape, Demski’s experience and vision are expected to play a crucial role in shaping its future initiatives.